Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia

Completed · Phase 4 · Has a placebo group

Conditions studied: Schizophrenia

In brief

This study will examine whether pretreatment with D-cycloserine before cognitive behavioral therapy can reduce impairments still present in people with stable cases of schizophrenia as well as determine which traits make schizophrenics most likely to respond to D-cycloserine treatment.

Key facts

Study ID

NCT00742079

Run by

Massachusetts General Hospital

People needed

21

Starts

2006-09-01

Expected to finish

2010-12-01

Last updated by the study team

2017-12-19

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Meets DSM-IV criteria for schizophrenia, schizoaffective disorder, or schizophrenia, paranoid subtype, based on chart review, Structured Clinical Interview for DSM-IV, and consultation with the patient's clinicians
• Medicated with an antipsychotic agent other than clozapine at a stable dose for at least 6 weeks
• Scores at least 3, or "moderate," on the Scale for the Assessment of Positive Symptoms global delusion rating
• Paranoid or referential delusional content
• Never engaged in formal CBT psychotherapy in the past

You may not qualify if…

• Diagnosis of a comorbid Axis I disorder other than schizophrenia
• Active substance abuse or dependence within 6 months
• Significant suicidal ideation within 6 weeks
• Pregnant or nursing
• Unstable medical disorder
• impaired renal clearance (creatinine <60mg/dL/min)
• Suffering from dementia
• Suffering from seizure disorder

Where it is running

• MGH Schizophrenia Program - Freedom Trail Clinic — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.